Overview

Pilocarpine, Brimonidine, Oxymetazoline (PBO) Compound to Control Presbyopia Symptoms

Status:
Recruiting
Trial end date:
2021-09-15
Target enrollment:
Participant gender:
Summary
Safety and Efficacy of Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac (PBOHB) ophthalmic compound to improve uncorrected near vision in healthy presbyopic patients one hour after instillation.
Phase:
Phase 1
Details
Lead Sponsor:
Optall Vision
Treatments:
Brimonidine Tartrate
Bromfenac
Hyaluronic Acid
Oxymetazoline
Phenylephrine
Pilocarpine